Eric Daugas Selected Research

mast cell protease 4

1/2020	Mast cell chymase protects against acute ischemic kidney injury by limiting neutrophil hyperactivation and recruitment.
8/2013	Mast cell chymase protects against renal fibrosis in murine unilateral ureteral obstruction.
7/2010	Mouse mast cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune complex-mediated glomerulonephritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Daugas Research Topics

Disease

12	Proteinuria 12/2021 - 07/2010
11	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 01/2002
10	Lupus Nephritis 04/2021 - 01/2002
8	Inflammation (Inflammations) 10/2022 - 07/2010
7	Glomerulonephritis 01/2022 - 03/2009
6	Kidney Diseases (Kidney Disease) 01/2022 - 07/2008
5	Renal Insufficiency (Renal Failure) 10/2022 - 10/2006
5	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2022 - 01/2007
5	Vasculitis (Vasculitides) 01/2022 - 02/2014
5	Nephritis 01/2018 - 06/2010
4	Infections 01/2022 - 03/2002
4	Neoplasms (Cancer) 01/2022 - 03/2002
4	Chronic Kidney Failure (Chronic Renal Failure) 01/2019 - 03/2012
4	IGA Glomerulonephritis (IGA Nephropathy) 01/2019 - 12/2011
4	Chronic Renal Insufficiency 10/2018 - 11/2012
4	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2018 - 11/2014
4	Fibrosis (Cirrhosis) 01/2018 - 01/2002
3	Tuberculosis (Tuberculoses) 01/2022 - 10/2006
3	Acute Kidney Injury (Acute Renal Failure) 02/2021 - 06/2006
3	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 12/2018 - 01/2007
3	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2018 - 02/2014
3	Microscopic Polyangiitis 01/2018 - 02/2014
2	Pathologic Complete Response 01/2022 - 11/2014
2	Hypertension (High Blood Pressure) 12/2021 - 01/2002
2	Ischemia 01/2021 - 12/2017
2	Reperfusion Injury 01/2020 - 12/2017
2	Systemic Vasculitis 01/2018 - 02/2014
2	Hematuria 08/2015 - 04/2012
2	Interstitial Nephritis (Tubulointerstitial Nephritis) 01/2008 - 01/2006
1	Rare Diseases (Rare Disease) 10/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Thrombotic Microangiopathies 12/2021
1	Hemolytic-Uremic Syndrome 01/2021
1	Mixed Connective Tissue Disease (MCTD) 01/2021
1	Necrosis 01/2020
1	Segmental glomerulosclerosis 03/2019
1	Sarcoidosis (Schaumann Disease) 02/2019
1	Malacoplakia 10/2018
1	Hypercalcemia (Milk Alkali Syndrome) 10/2018
1	Multiple Myeloma 10/2018
1	Purpura 01/2018

Drug/Important Bio-Agent (IBA)

8	Rituximab (Mabthera)FDA Link 01/2018 - 01/2007
7	AutoantibodiesIBA 01/2022 - 06/2010
7	Immunoglobulin G (IgG)IBA 01/2022 - 12/2011
6	AntibodiesIBA 01/2022 - 01/2008
6	SteroidsIBA 01/2022 - 10/2006
6	Immunoglobulin A (IgA)IBA 01/2019 - 12/2011
6	CreatinineIBA 01/2018 - 01/2002
4	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2022 - 02/2014
4	Biological ProductsIBA 12/2021 - 06/2006
4	Immunoglobulin E (IgE)IBA 01/2021 - 06/2010
4	Chymases (Chymase)IBA 12/2020 - 07/2010
4	Antigen-Antibody Complex (Immune Complex)IBA 01/2019 - 07/2010
3	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2018
3	mast cell protease 4IBA 01/2020 - 07/2010
3	CalciumIBA 10/2018 - 02/2018
3	Parathyroid Hormone (Parathormone)IBA 10/2018 - 02/2018
3	Azathioprine (Imuran)FDA LinkGeneric 01/2018 - 11/2014
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 07/2017
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 03/2009
2	Complement System Proteins (Complement)IBA 10/2022 - 01/2018
2	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 10/2022 - 01/2018
2	Complement C3 Nephritic FactorIBA 10/2022 - 01/2018
2	Mycophenolic Acid (Cellcept)FDA LinkGeneric 12/2018 - 11/2011
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2018 - 03/2009
2	Phosphorus (Red Phosphorus)IBA 10/2018 - 02/2018
2	MineralsIBA 10/2018 - 02/2018
2	Phosphates (Orthophosphate)IBA 10/2018 - 02/2018
2	IgA receptor (protein B)IBA 08/2015 - 04/2012
1	EndopeptidasesIBA 01/2022
1	Peptides (Polypeptides)IBA 04/2021
1	U1 Small Nuclear RibonucleoproteinIBA 01/2021
1	Shiga Toxin (Shigella Toxin)IBA 01/2021
1	CC ChemokinesIBA 01/2021
1	AutoantigensIBA 01/2021
1	Small Nuclear Ribonucleoproteins (snRNP)IBA 01/2021
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 12/2020
1	Angiotensin IIIBA 12/2020
1	Peroxidase (Myeloperoxidase)IBA 01/2020
1	IntegrinsIBA 01/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2019
1	Vitamin D FDA LinkGeneric 10/2018
1	25-Hydroxyvitamin D3 1-alpha-Hydroxylase (25 Hydroxyvitamin D3 1 alpha Hydroxylase)IBA 10/2018
1	1,25-dihydroxyvitamin DIBA 10/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	Interleukin-10 (Interleukin 10)IBA 01/2018
1	Interleukin-8 (Interleukin 8)IBA 01/2018
1	Immunoglobulin M (IgM)IBA 01/2018
1	eculizumab FDA Link 01/2018
1	galactosyl-deficient IgA1IBA 01/2018
1	IronIBA 12/2017
1	Amyloid (Amyloid Fibrils)IBA 12/2017
1	pristane (pristan)IBA 11/2017
1	Serum AlbuminIBA 07/2017

Therapy/Procedure

12	Therapeutics 01/2022 - 06/2006
4	Highly Active Antiretroviral Therapy (HAART) 03/2012 - 02/2005
3	Renal Replacement Therapy (Therapies, Renal Replacement) 02/2021 - 11/2012
1	Conservative Treatment 01/2021
1	Plasma Exchange 01/2018